PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7541423-6	1995	Pretreatment of cells with the glucocorticoid budesonide (10(-10)-10(-7) M) for 24 h inhibited expression of RANTES mRNA and protein stimulated by either TNF-alpha or TNF-alpha plus IFN-gamma in a concentration- and time-dependent manner.	Budesonide	46-56	C-C motif chemokine ligand 5	Homo sapiens	109-115	
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	C-C motif chemokine ligand 5	Homo sapiens	226-232	
14643170-2	2004	This study was performed to investigate the effectiveness of the commonly used steroids beclomethasone, budesonide and fluticasone in downregulating HASMC production of RANTES and IL-8.	Budesonide	104-114	C-C motif chemokine ligand 5	Homo sapiens	169-175	
10553092-7	1999	Although budesonide inhibited the expression of chemokine mRNA to a variable extent, it effectively inhibited production of eotaxin and RANTES protein.	Budesonide	9-19	C-C motif chemokine ligand 5	Homo sapiens	136-142	
10553092-8	1999	Budesonide inhibited both RANTES- and eotaxin promoter-driven reporter gene activity.	Budesonide	0-10	C-C motif chemokine ligand 5	Homo sapiens	26-32	
18504402-0	2008	Inhibitory effect of budesonide alone and in combination with formoterol on IL-5 and RANTES production from mononuclear cells.	Budesonide	21-31	C-C motif chemokine ligand 5	Homo sapiens	85-91	
14643170-5	2004	Pre-treatment with beclomethasone, budesonide or fluticasone reduced TNFalpha- and IL-1beta-stimulated IL-8 and RANTES release from HASMC in a dose dependent manner.	Budesonide	35-45	C-C motif chemokine ligand 5	Homo sapiens	112-118	
14643170-7	2004	TNFalpha- and IL-1beta-induced RANTES and IL-8 expression was reduced on the transcriptional level by pre-treatment with fluticasone and budesonide.	Budesonide	137-147	C-C motif chemokine ligand 5	Homo sapiens	31-37	
14643170-8	2004	The results suggest that the topical steroids fluticasone, budesonide and to a lesser extent beclomethasone may have beneficial effects on airway inflammation in asthma by reducing RANTES and IL-8-induced leukocyte infiltration into the airway wall.	Budesonide	59-69	C-C motif chemokine ligand 5	Homo sapiens	181-187	
10553092-2	1999	We investigated whether cytokines and the topical glucocorticoid budesonide differentially regulate RANTES, monocyte chemoattractant protein-4 (MCP-4), and eotaxin mRNA and protein expression in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells by Northern blot analysis and ELISAs.	Budesonide	65-75	C-C motif chemokine ligand 5	Homo sapiens	100-106	
23183768-7	2012	Budesonide and calcitriol administered in 1:3 ratio and budesonide and tacalcitol in 1:1 and 1:3 reduced RANTES concentration significantly better than each of the drug used in monotherapy (p<0.05).	Budesonide	56-66	C-C motif chemokine ligand 5	Homo sapiens	105-111	
23183768-8	2012	Budesonide and tacalcitol in 1:1 and 1:3 ratios suppressed RANTES production to the lowest level (171.8+-97.6pg/ml and 178.7+-105.22pg/ml, respectively).	Budesonide	0-10	C-C motif chemokine ligand 5	Homo sapiens	59-65	
21148795-3	2011	Cell treatment with the potent GC budesonide accelerated the decay of CCL2 mRNA (t(1/2) = 8 +- 1 min versus 62 +- 17 min in DMSO-treated cells) and CCL7 mRNA (t(1/2) = 15 +- 4 min versus 114 +- 37 min), but not that of CCL5 mRNA (t(1/2)=231 +- 8 min versus 266 +- 5 min) in the BEAS-2B cell line.	Budesonide	34-44	C-C motif chemokine ligand 5	Homo sapiens	219-223